SLCO1B1 gene variability influences lipid-lowering efficacy on simvastatin therapy in Southern Brazilians

2012 ◽  
Vol 50 (3) ◽  
Author(s):  
Vinicius A. Sortica ◽  
Marilu Fiegenbaum ◽  
Luciana O. Lima ◽  
Cézar R. Van der Sand ◽  
Luis C. Van der Sand ◽  
...  
Keyword(s):  
Lipid Lowering ◽  
Simvastatin Therapy ◽  
Slco1b1 Gene ◽  
Gene Variability

Traditional Chinese medication Tongxinluo dose-dependently enhances stability of vulnerable plaques: a comparison with a high-dose simvastatin therapy

2009 ◽  
Vol 297 (6) ◽  
pp. H2004-H2014 ◽  
Author(s):  
Lei Zhang ◽  
Yan Liu ◽  
Xiao Ting Lu ◽  
Yi Ling Wu ◽  
Cheng Zhang ◽  
...  
Keyword(s):  
Plaque Rupture ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Lipid Lowering ◽  
Control Group ◽  
High Dose ◽  
Treatment Groups ◽  
Simvastatin Therapy ◽  
Aortic Plaques ◽  
All Treatment

This study was carried out to test the hypothesis that Tongxinluo (TXL) as a Chinese herbal medicine enhances stability of vulnerable plaque dose dependently via lipid-lowering and anti-inflammation effects, similar to a high-dose simvastatin therapy. After abdominal aortic balloon injury, 75 rabbits were fed a 1% cholesterol diet for 10 wk and were then divided into five groups for 8-wk treatment: control group, low-dose TXL group, moderate-dose TXL group, high-dose TXL group, and high-dose simvastatin group. At the end of week 16, an adenovirus containing p53 was injected into the abdominal aortic plaques. Two weeks later, plaque rupture was induced by pharmacological triggering. The incidence of plaque rupture in all treatment groups (14.3%, 7.1%, 7.7%, and 7.1%) was significantly lower than that in control group (73.3%; P > 0.01). TXL dose-dependently lowered serum lipid levels and inhibited systemic inflammation. Corrected acoustic intensity and fibrous cap thickness of the aortic plaques were significantly increased, whereas plaque area, plaque burden, vulnerable index, and expression of oxidized low-density lipoprotein (ox-LDL) receptor 1, matrix metalloproteinase 1 (MMP-1), MMP-3, tissue inhibitor of MMP 1, and NF-κB in plaques were markedly reduced in all treatment groups when compared with the control group. Similar to high-dose simvastatin group, high-dose TXL group exhibited a low serum level of low-density lipoprotein cholesterol and ox-LDL, a low expression level of systemic and local inflammatory factors and a low plaque vulnerability index, with no differences in the incidence of plaque rupture among all treatment groups. TXL dose-dependently enhances the stability of vulnerable plaques and prevents plaques from rupture. Simvastatin and TXL offer similar protection in terms of lipid-lowering, anti-inflammation, and antioxidation effects.

Lack of association between SLCO 1B1 polymorphisms and lipid‐lowering response to simvastatin therapy in Thai hypercholesterolaemic patients

2018 ◽  
Vol 43 (5) ◽  
pp. 647-655 ◽  
Author(s):  
N. Kaewboonlert ◽  
W. Thitisopee ◽  
W. Sirintronsopon ◽  
S. Porntadavity ◽  
N. Jeenduang
Keyword(s):  
Lipid Lowering ◽  
Simvastatin Therapy

Advantages Seen With Early Lipid Lowering

2011 ◽  
Vol 44 (8) ◽  
pp. 12
Author(s):  
CAROLINE HELWICK
Keyword(s):  
Lipid Lowering
Sign in / Sign up

Export Citation Format

Share Document